"Florida Cancer Specialists provides the most advanced cancer treatment options available, close to home, and personalized for each patient’s unique needs. At our Tallahassee Cancer Center, we provide treatment for all forms of cancers and blood disorders, including laboratory, pharmacy, gynecologic oncology, nutritional counseling and care management. Clinical trials and Dignicap® available."

During the past decade, SCRI Florida Cancer Specialists PAN conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "SCRI Florida Cancer Specialists PAN" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "Arcus Biosciences, Inc." with 1 trials sponsored, "Celgene" with 1 trials sponsored, "Genentech, Inc." with 1 trials sponsored and "Mirati Therapeutics Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "SCRI Florida Cancer Specialists PAN" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Flatiron Health, Inc.; Foundation Medicine, Inc." with 1 trials as a collaborator and "Gilead Sciences" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "SCRI Florida Cancer Specialists PAN" are "Advanced Upper Gastrointestinal Tract Adenocarcinoma" (1 trials), "Breast Cancer" (1 trials), "Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer" (1 trials), "Metastatic Non-Squamous Non-Small Cell Lung Cancer" (1 trials) and "Myelodysplastic Syndromes" (1 trials). Many other conditions were trialed in "SCRI Florida Cancer Specialists PAN" in a lesser frequency.

Most popular intervention types in "SCRI Florida Cancer Specialists PAN" are "Drug" (8 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (3 trials), "Tiragolumab" (3 trials), "Nivolumab" (2 trials), "Palbociclib" (2 trials) and "Placebo" (2 trials). Other intervention names were less common.

The vast majority of trials in "SCRI Florida Cancer Specialists PAN" are 9 trials for "All" genders.

Currently, there are NaN active trials in "SCRI Florida Cancer Specialists PAN". undefined are not yet recruiting, 3 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in SCRI Florida Cancer Specialists PAN, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in SCRI Florida Cancer Specialists PAN, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".